New 2023 Study concludes Testosterone-Replacement Therapy as Safe for Cardiovascular Health
Did you know that low testosterone in men, also known as hypogonadism, can lead to various undesirable symptoms? These symptoms include low libido, decreased energy, changes in mood, loss of muscle mass and body hair, and even erectile difficulties.
But don’t worry, there is a treatment called testosterone-replacement therapy (TRT) that can help improve these symptoms in men. Previous studies have shown that men with hypogonadism who undergo TRT experience enhanced sexual function, improved bone mineral density, and reduced symptoms of depression.
However, when it comes to TRT, there has been some concern and conflicting data regarding its potential effects on cardiovascular health. It turns out, men with hypogonadism already have an increased risk of developing cardiovascular disease. Moreover, certain studies have suggested that TRT might also have some cardiovascular risks. So, it’s crucial for both patients and health care providers to carefully weigh the potential risks and benefits of TRT, especially for patients who already have existing cardiovascular conditions.
To shed more light on this important topic, the Food and Drug Administration (FDA) has issued guidance to testosterone product manufacturers, requiring them to conduct clinical trials specifically focused on the cardiovascular safety of TRT. As a result, the Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficiency Response in Hypogonadal Men (TRAVERSE) trial was initiated.
The TRAVERSE study aimed to determine whether TRT poses a greater risk for cardiovascular events in men receiving therapy. A large group of 5,246 men between the ages of 45 to 80 years who either had preexisting cardiovascular disease or were at high risk of developing it, and also had confirmed hypogonadism, participated in this trial. These men were then randomly assigned to one of two groups – the TRT group or the placebo group – at a 1:1 ratio. Ultimately, 5,198 participants received at least one dose of either TRT or placebo, with half receiving the TRT and the other half receiving placebo. Such treatments went on for for an average duration of 22 months.
This groundbreaking clinical trial will provide us with valuable insights into the potential risks and benefits of TRT for men with hypogonadism and cardiovascular concerns.
Interestingly, the study revealed that the overall occurrence of adverse cardiac events was relatively low in both the TRT group and the control group. Specifically, cardiovascular events were observed in 7.0% of patients receiving testosterone replacement therapy (TRT) and in 7.3% of patients in the control group throughout the study duration. This suggests that there was no significant difference in the rate of cardiovascular events between men on TRT and those not on TRT. However, it is worth noting that patients receiving TRT did experience higher rates of atrial fibrillation (cardiac arrhythmia), acute kidney injury, and pulmonary embolism.
These findings provide valuable insights into the cardiovascular safety of TRT. As a result, the study authors recommend that patients and healthcare providers can now make better-informed decisions regarding the use of TRT, particularly for individuals who may be at risk of cardiovascular disease.
It is Important to remember that as it relates to starting appropriate Testosterone Therapy, It is best to consult a physician who is specialized in the field of Hormone Optimization Therapy. Such physician will do a comprehensive evaluation and appropriate monitoring to ensure optimal results and health benefits.